Hydrogen/Minocycline for Ischemic Stroke

Stony Brook University Hospital, Stony Brook, NY
Hydrogen +3 morePhase 2 & 3RecruitingLed by Adrian Marchidann, MDResearch Sponsored by Stony Brook University

Study Summary

This trialstudies a possible new treatment for stroke that combines two drugs to help improve neurological recovery.

Eligible Conditions
  • Ischemic Stroke

Eligibility Criteria

Inclusion Criteria

You will be eligible if you check “Yes” for the criteria below
Your stroke severity score, called the National Institute of Health Stroke Scale (NIHSS), is 5 or higher when you first join the study.


Screening ~ 3 weeks
Treatment ~ Varies
Follow ups ~ 90 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 90 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Secondary outcome measures
NIH Stroke Scale (NIHSS)
simplified modified Rankin Scale (sMRSq)

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Hydrogen/MinocyclineExperimental Treatment2 Interventions
Hydrogen will be infused into aqueous solution (normal saline or water) at as high a concentration as possible (saturation = 1.6 ppm), and administered intravenously or orally respectively, TID for 3 days. Similarly, Minocycline will be administered either i.v. or p.o. once daily for 5 days.
Group II: Placebo Hydrogen/Placebo MinocyclinePlacebo Group2 Interventions
Normal saline will be substituted for both Hydrogen and Minocycline for intravenous administration. Water will be substituted for hydrogen when administered p.o., and placebo capsules will be substituted for minocycline.
First Studied
Drug Approval Stage
How many patients have taken this drug
Not yet FDA approved
FDA approved

Find a site

Who is running the clinical trial?

Korea Institute of Science and TechnologyOTHER
5 Previous Clinical Trials
4,473 Total Patients Enrolled
Stony Brook UniversityLead Sponsor
204 Previous Clinical Trials
36,308 Total Patients Enrolled
Adrian Marchidann, MDPrincipal Investigator
Stony Brook University Hospital
Dennis Choi, MD, PhDStudy Director
Stony Brook University Hospital

Media Library

Hydrogen (Other) Clinical Trial Eligibility Overview. Trial Name: NCT03320018 — Phase 2 & 3
Ischemic Stroke Research Study Groups: Hydrogen/Minocycline, Placebo Hydrogen/Placebo Minocycline
Ischemic Stroke Clinical Trial 2023: Hydrogen Highlights & Side Effects. Trial Name: NCT03320018 — Phase 2 & 3
Hydrogen (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03320018 — Phase 2 & 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many individuals are being monitored in this experiment?

"That is correct, according to the clinicaltrials.gov website this study is open for recruitment. The listing went up on 8/2/2017 with the most recent update being 11/14/2022. They are looking for a total of 100 patients from 1 location."

Answered by AI

Are there other instances of Hydrogen/Minocycliine being used in a medical context?

"As of now, there are 30 ongoing studies examining the effects of Hydrogen/Minocycliine. Of these 30 trials, 9 have progressed to Phase 3 testing. Most of the research being conducted for Hydrogen/Minocycliine is happening in Guangzhou, Guangdong; however, 525 different locations around the world are running clinical trials for this medication."

Answered by AI

Is this clinical trial looking for more participants?

"Yes, this information can be found on the clinicaltrials.gov website. The trial was first posted on 8/2/2017 and has since been updated on 11/14/2022."

Answered by AI

To what ailment is Hydrogen/Minocycliine most often applied?

"Rocky Mountain spotted fever is most commonly treated with the hydrogen/minocycliine drug cocktail. This treatment method is also effective for other conditions such as q fever, dental root planing, and respiratory tract infections."

Answered by AI
~15 spots leftby Nov 2024